{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:51:39Z","timestamp":1772347899095,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40266-020-00801-x","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T05:05:30Z","timestamp":1605675930000},"page":"899-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5190-9191","authenticated-orcid":false,"given":"Raquel","family":"Freitas","sequence":"first","affiliation":[]},{"given":"F\u00e1tima","family":"Godinho","sequence":"additional","affiliation":[]},{"given":"Nathalie","family":"Madeira","sequence":"additional","affiliation":[]},{"given":"Bruno Miguel","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Fl\u00e1vio","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Santiago","sequence":"additional","affiliation":[]},{"given":"Agna","family":"Neto","sequence":"additional","affiliation":[]},{"given":"Soraia","family":"Azevedo","sequence":"additional","affiliation":[]},{"given":"Maura","family":"Couto","sequence":"additional","affiliation":[]},{"given":"Gra\u00e7a","family":"Sequeira","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Madruga","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Bernardes","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Joaquim Polido","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"issue":"10","key":"801_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","volume":"9","author":"AM Boots","year":"2013","unstructured":"Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(10):604\u201313.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"801_CR2","first-page":"e002468","volume":"3","author":"B Ng","year":"2013","unstructured":"Ng B, Chu A, Khan MM. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ. 2013;3(4):e002468.","journal-title":"BMJ"},{"key":"801_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40744-015-0021-z","volume":"2","author":"K Morsley","year":"2015","unstructured":"Morsley K, Kilner T, Steuer A. Biologics prescribing for rheumatoid arthritis in older patients: a single-center retrospective cross-sectional study. Rheumatol Ther. 2015;2:165\u201372.","journal-title":"Rheumatol Ther."},{"key":"801_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2165\/11316460-000000000-00000","volume":"26","author":"B Radovits","year":"2009","unstructured":"Radovits B, Kievit W, Laan R. Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. Drugs Aging. 2009;26:647\u201364.","journal-title":"Drugs Aging"},{"key":"801_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/art.22688","volume":"57","author":"S Genevay","year":"2007","unstructured":"Genevay S, Finckh A, Ciurea A. Tolerance and effectiveness of anti-tumor necrosis factor a therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Care Res. 2007;57:679\u201385.","journal-title":"Arthritis Care Res."},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/ard.2005.035287","volume":"65","author":"R Fleischmann","year":"2006","unstructured":"Fleischmann R, Baumgartner SW, Weisman MH. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379\u201384.","journal-title":"Ann Rheum Dis"},{"key":"801_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"J Galloway","year":"2011","unstructured":"Galloway J, Hyrich K, Mercer L. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6\u00a0months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/keq242.","journal-title":"Rheumatology (Oxford)"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00002512-200926040-00001","volume":"26","author":"A D\u00edaz-Borj\u00f3n","year":"2009","unstructured":"D\u00edaz-Borj\u00f3n A. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging. 2009;26:273.","journal-title":"Drugs Aging"},{"key":"801_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-017-1324-y","volume":"19","author":"DM Boeters","year":"2017","unstructured":"Boeters DM, Mangnus L, Ajeganova S, Lindqvist E, Svensson B, Toes EM, et al. The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Res Ther. 2017;19:115.","journal-title":"Arthritis Res Ther."},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar4540","volume":"16","author":"L Innala","year":"2014","unstructured":"Innala L, Berglin E, M\u00f6ller B, Ljung L, Smedby T, Sodergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2014;16:R94.","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"801_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40744-015-0021-z","volume":"2","author":"K Morsley","year":"2015","unstructured":"Morsley K, Kilner T, Steuer A. Biologics prescribing for rheumatoid arthritis in older patients: a single-center retrospective cross-sectional study. Rheumatol Ther. 2015;2(2):165\u201372.","journal-title":"Rheumatol Ther."},{"key":"801_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IBT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22\u201332.","journal-title":"Arthritis Rheum"},{"key":"801_CR13","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ, Symmons DPM. Predictors of response to anti-TNF-\u03b1 therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2006;45:1558\u201365.","journal-title":"Rheumatology"},{"key":"801_CR14","unstructured":"Edwards CJ,\u00a0Roshak K,\u00a0Bukowski JF,\u00a0Pedersen R,\u00a0Thakur M,\u00a0Marshall L, et al. Efficacy of etanercept in elderly patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;69(suppl 10)."},{"issue":"4","key":"801_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s40064-015-0979-6","volume":"1","author":"RH Mohammed","year":"2015","unstructured":"Mohammed RH, Farahat F, Kewan HH, Bukhari MA. Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease. Springerplus. 2015;1(4):207.","journal-title":"Springerplus."},{"key":"801_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/acr.21812","volume":"65","author":"J Widdifield","year":"2013","unstructured":"Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65:353.","journal-title":"Arthritis Care Res."},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3899\/jrheum.101009","volume":"38","author":"Y Komano","year":"2011","unstructured":"Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011;38:125.","journal-title":"J Rheumatol"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00801-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-020-00801-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00801-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T06:12:12Z","timestamp":1606716732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-020-00801-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00801-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"19 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Raquel Freitas, F\u00e1tima Godinho, Nathalie Madeira, Bruno Miguel Fernandes, Fl\u00e1vio Costa, Mariana Santiago, Agna Neto, Soraia Azevedo, Maura Couto, Gra\u00e7a Sequeira, Jo\u00e3o Madruga Dias, and Lu\u00eds Miranda have no conflicts of interest that are directly relevant to the content of this study. Miguel Bernardes is on the advisory boards of Lilly, Biogen, and Abbvie (fees\u2009<\u2009$10,000). Joaquim Polido-Pereira is on the advisory boards of Pfizer, MSD, and Abbvie (fees\u2009<\u2009$10,000). Jo\u00e3o Eurico Fonseca receives consultancy and speaking fees for Pfizer, UCB, Jansen, Roche, MSD, Novartis, Abbvie, and Lilly (fees\u2009<\u2009$10,000). Maria Jos\u00e9 Santos receives consultancy and speaking fees for Pfizer and Abbvie (fees\u2009<\u2009$10,000).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Reuma.pt was approved by the National Data Protection Authority and the ethics committee of each participating center. This study was approved by the Ethics Committee of Hospital Garcia de Orta, Almada, Portugal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients registered in the database Reuma.pt provided written informed consent for data collection and analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients registered in the database Reuma.pt provided written informed consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The database generated and analyzed during the study is not publicly available due to ethical and law restrictions.\u00a0The data that support the findings of this study are available on request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study protocol and analysis plan was drafted by R Freitas and MJ Santos and revised by all the authors. Data analyses and draft of the manuscript were done by R Freitas. All authors contributed substantially for study conception, data acquisition and interpretation, revised the final manuscript for important intellectual content and approved the final version submitted for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}